Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on PCSK9 (Jan 2019)

Posted by Matt Breese on Jan 18, 2019

Find me on:

According to our recent payer coverage analysis for PCSK9 inhibitors, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for PCSK9 inhibitors shows that more than 90% of the lives under the pharmacy benefit in commercial and health exchange formularies have utilization management restrictions. 

MMIT-Reality Check-PCSK9_1Q2019Data snapshot as of Q1 2019

Trends: In October 2018, Amgen said that it would reduce the price of its Repatha SureClick autoinjector to $5,850 per year. 

To read the full Reality Check on PCSK9 inhibitors with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing